In a more recent study [144], the efficacy of a redox-responsive lipid–polymer hybrid NP platform to deliver p53-encoding synthetic mRNA has been tested in cultured Hep3B and H1299 cancer cell lines as well as in different orthotopic and disseminated mouse tumor models (the p53 tumor suppressor gene undergo alteration in various cancers). The gene discussed is TP53; the disease is cancer.